Biomune Systems Inc. has completed a private placement of thecompany's series "B" preferred stock that brought in $5.4 million. Thestock was disposed of for $15 a share to a single institutional buyer.The funds will be used to continue the development of the company'sdrug, Immuno-C, for the treatment of cryptosporidiosis. The disease,with acute gastro-intestinal symptoms, can be fatal to people withweakened immune systems, such as AIDS patients.The Salt Lake City company's series "B" stock carries a 10 percentcumulative dividend payable in either cash or additional preferredstock. Each preferred share can be converted into one common sharebefore January 1996. _ Philippa Maister
(c) 1997 American Health Consultants. All rights reserved.